Researchers from Nagoya University, led by Assoc. Prof. Naoki Sunaguchi, employed X-ray dark-field computed tomography to create three-dimensional renderings of the internal structure of the human nipple, thereby elucidating its varied arrangements. Their approach could be applied for diagnostic and exploratory purposes in breast cancer.
Data for 950,000 black, white, Asian and Hispanic patients in the U.S. diagnosed with prostate, ovarian, breast, stomach, pancreatic, lung, liver, esophageal, or colorectal cancers were analyzed to examine differences by race and ethnicity in stage at diagnosis, use of therapy, overall survival and cancer-specific survival.
Consuming a diet high in fiber was linked with a reduced incidence of breast cancer in an analysis of all relevant prospective studies. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS).
An increased proportion of Indigenous American (IA) ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
An analysis of a large Swedish cohort revealed that breast density, microcalcifications, and masses are heritable features, and that breast density and microcalcifications were positively associated with a genetic predisposition to breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
They identified a protein that, like a switch, controls the onset of cell death processes in cancer cells, which are regulated by p53, the protein known as 'the guardian of the genome.' The findings will be used to develop more tailored and effective cancer treatments.
Researchers say they have found a viable new therapeutic strategy for estrogen receptor-positive (ER+) breast cancer, even cancers that are resistant to current standard of care treatments. They will present the results of their new preclinical study accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated, often before there are any signs of the disease. The test has a false positive rate of less than 1% meaning that less than 1% of people would be wrongly identified as having cancer. It can correctly predict the tissue in which the cancer originated in 93% of samples. The study is published in Annals of Oncology.
Nearly 200 radiologists who interpreted about 251,000 digital breast tomosynthesis (DBT) and 2 million digital mammography screening examinations were included in this observational study that evaluated recall and cancer detection rates.
Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and 'second generation' approaches are needed. Now, a team of Penn State engineers may have a way to predict which mutations will occur in people, creating an easier path to create effective pharmaceuticals.